Privia Health Group, Inc. (NASDAQ:PRVA) Director William M. Sullivan Sells 18,153 Shares

Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) Director William M. Sullivan sold 18,153 shares of the firm’s stock in a transaction dated Friday, January 20th. The shares were sold at an average price of $25.36, for a total value of $460,360.08. Following the transaction, the director now owns 5,808,777 shares in the company, valued at $147,310,584.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Privia Health Group Stock Down 2.8 %

PRVA stock opened at $24.82 on Wednesday. Privia Health Group, Inc. has a twelve month low of $17.99 and a twelve month high of $44.64. The company has a market cap of $2.84 billion, a PE ratio of -68.94 and a beta of 0.67. The business’s 50-day simple moving average is $23.64 and its 200 day simple moving average is $31.38.

Privia Health Group (NASDAQ:PRVA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported $0.01 earnings per share for the quarter. Privia Health Group had a negative return on equity of 6.82% and a negative net margin of 3.02%. The business had revenue of $342.90 million for the quarter, compared to the consensus estimate of $323.66 million. On average, equities research analysts anticipate that Privia Health Group, Inc. will post -0.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PRVA shares. Truist Financial cut their target price on Privia Health Group to $41.00 in a report on Thursday, November 17th. Stifel Nicolaus started coverage on Privia Health Group in a report on Thursday, December 8th. They set a “buy” rating and a $28.00 target price on the stock. Canaccord Genuity Group cut their target price on Privia Health Group from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, November 11th. SVB Leerink lowered their price target on Privia Health Group from $46.00 to $39.00 and set an “outperform” rating on the stock in a research report on Friday, November 11th. Finally, BTIG Research lowered their price target on Privia Health Group from $45.00 to $40.00 in a research report on Monday, January 9th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $39.46.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors have recently added to or reduced their stakes in PRVA. Assetmark Inc. boosted its holdings in Privia Health Group by 119.4% during the second quarter. Assetmark Inc. now owns 893 shares of the company’s stock valued at $26,000 after purchasing an additional 486 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Privia Health Group by 4,330.4% during the second quarter. First Horizon Advisors Inc. now owns 1,019 shares of the company’s stock valued at $29,000 after purchasing an additional 996 shares in the last quarter. Signaturefd LLC acquired a new stake in Privia Health Group during the third quarter valued at approximately $32,000. Focused Wealth Management Inc acquired a new stake in Privia Health Group during the fourth quarter valued at approximately $41,000. Finally, Nisa Investment Advisors LLC acquired a new stake in Privia Health Group during the second quarter valued at approximately $46,000. 66.83% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.